EUVIMEDEUVIMED entdecken
Leserbrief

Interpreting Clonal Hematopoiesis Following [ 177 Lu]Lu-PSMA-617: Clinical Risk Versus Genomic Signal

Swayamjeet Satapathy, Piyush Aggarwal, Ashwani Sood

Journal of Nuclear Medicine · 2026-06 · 67 (6) · 1007-1007

DOI: 10.2967/jnumed.126.272410 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 26.03.2026. Verfasst von Swayamjeet Satapathy und 2 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Satapathy, S., Aggarwal, P., & Sood, A. (2026). Interpreting Clonal Hematopoiesis Following [ 177 Lu]Lu-PSMA-617: Clinical Risk Versus Genomic Signal. Journal of Nuclear Medicine, 67(6), 1007-1007. https://doi.org/10.2967/jnumed.126.272410

Vancouver

Satapathy S, Aggarwal P, Sood A. Interpreting Clonal Hematopoiesis Following [ 177 Lu]Lu-PSMA-617: Clinical Risk Versus Genomic Signal. Journal of Nuclear Medicine. 2026;67(6):1007-1007. doi:10.2967/jnumed.126.272410

BibTeX
@article{Satapathy2026,
  author = {Satapathy, Swayamjeet and Aggarwal, Piyush and Sood, Ashwani},
  title = {Interpreting Clonal Hematopoiesis Following [ 177 Lu]Lu-PSMA-617: Clinical Risk Versus Genomic Signal},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {6},
  pages = {1007--1007},
  doi = {10.2967/jnumed.126.272410}
}
Kostenlos starten →